Teleflex ( (TFX) ) has released its Q4 earnings. Here is a breakdown of the information Teleflex presented to its investors.
Teleflex Incorporated is a global provider of medical technologies, offering a diverse portfolio of products in areas such as anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology. The company is known for its commitment to improving health and quality of life through innovative healthcare solutions.
In its latest earnings report, Teleflex reported a revenue of $795.4 million for the fourth quarter of 2024, reflecting a 2.8% increase from the previous year. The company also highlighted a significant growth in adjusted diluted earnings per share, which rose to $3.89 from $3.38 in the prior year period. For the full year, Teleflex achieved a GAAP revenue of $3,047.3 million, marking a 2.4% increase compared to the previous year.
Key financial metrics from the report include a notable performance in the Interventional and Surgical segments, which helped offset declines in Interventional Urology revenues. The company also announced a strategic acquisition of BIOTRONIK’s Vascular Intervention business, which is expected to complement its existing product suite. Additionally, Teleflex plans to separate into two publicly traded entities, RemainCo and NewCo, to streamline operations and enhance management focus.
Looking ahead, Teleflex has provided a 2025 guidance with a GAAP revenue growth range of -0.4% to 0.7% and an adjusted constant currency revenue growth range of 1.0% to 2.0%. The company also anticipates adjusted diluted earnings per share to be between $13.95 and $14.35, reflecting a cautious yet optimistic outlook for the coming year.
Overall, Teleflex’s diversified portfolio and strategic initiatives position it well for future growth, despite some challenges in specific segments. The company’s focus on innovation and strategic acquisitions is expected to drive long-term value for shareholders.